貧血およびその他の血液疾患治療薬の世界市場レポート 2025年

貧血およびその他の血液疾患治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には160億9,000万米ドルに成長し、CAGRは6.8%となります。予測期間の成長は、新興市場、世界の人口動態、経済的要因に起因すると考えられます。予測期間の主な動向には、研究開発、技術進歩、生物製剤と標的治療、遺伝子治療、遠隔医療と遠隔モニタリング、希少疾病用医薬品の指定、合併・買収などがあります。

世界の貧血の有病率の上昇は市場の重要な促進要因です。不健康なライフスタイル、食事パターンの変化、ストレスレベルの高まりが、世界中で貧血患者の増加を招いています。その一例として、貧血は高齢者層における一般的な健康問題となっており、65歳以上の有病率は約17%に達しています。世界銀行の報告によると、貧血は女性や若い人の間で8番目に多い病気です。このような貧血の増加は、貧血およびその他の血液疾患治療薬市場の成長に寄与しています。

個別化医療に対する需要の高まりが貧血およびその他の血液疾患治療薬市場の成長を促進すると予想されます。個別化医療では、個人の遺伝子プロファイルを使用して、病気の予防、診断、治療に関する意思決定を行う。このアプローチは、貧血やその他の血液疾患に対して、より効果的で正確に的を絞った治療を提供し、患者の健康状態をより良く、より長続きさせることにつながり、医療をより効率的かつ効果的にします。例えば、2023年3月、米国食品医薬品局（FDA）の医薬品評価研究センター（CDER）は、2022年に37の新規分子生物学的製剤（NME）を承認したが、このうち約12の治療用NMEは個別化医療連合（PMC）によって個別化医薬品に分類されています。したがって、個別化医療に対する需要の高まりが貧血およびその他の血液疾患治療薬市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界貧血およびその他の血液疾患治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の貧血およびその他の血液疾患治療薬市場：成長率分析
• 世界の貧血およびその他の血液疾患治療薬市場の実績：規模と成長, 2019-2024
• 世界の貧血およびその他の血液疾患治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界貧血およびその他の血液疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の貧血およびその他の血液疾患治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鉄欠乏性貧血
• 慢性腎臓病貧血
• 鎌状赤血球貧血
• 再生不良性貧血
• 世界の貧血およびその他の血液疾患治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界の貧血およびその他の血液疾患治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 薬局
• 世界の貧血およびその他の血液疾患治療薬市場鉄欠乏性貧血の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口鉄サプリメント
• 注射用鉄サプリメント
• 鉄分強化食品
• 世界の貧血およびその他の血液疾患治療薬市場慢性腎臓病性貧血のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 赤血球造血刺激因子製剤（ESA）
• 鉄サプリメント
• 輸血
• 世界の貧血およびその他の血液疾患治療薬市場鎌状赤血球貧血の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒドロキシウレア
• 輸血
• 遺伝子治療
• 疼痛管理薬
• 世界の貧血およびその他の血液疾患治療薬市場再生不良性貧血の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制療法
• 幹細胞移植
• 赤血球造血刺激因子製剤（ESA）

第7章 地域別・国別分析

• 世界の貧血およびその他の血液疾患治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の貧血およびその他の血液疾患治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 貧血およびその他の血液疾患治療薬市場：競合情勢
• 貧血およびその他の血液疾患治療薬市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Akebia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• F. Hoffmann-La Roche Ltd.
• Merck Sharp & Dohme Corp.
• Novartis AG
• Global Blood Therapeutics Inc.
• GlycoMimetics Inc.
• Eli Lilly and Company
• FibroGen Inc.
• bluebird bio Inc.
• Acceleron Pharma Inc.
• AMAG Pharmaceuticals Inc.
• Pieris Pharmaceuticals Inc.
• Vifor Pharma Management Ltd.
• Sanofi S.A.
• Allergan U.S. Inc.
• Meda Consumer Healthcare Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 貧血およびその他の血液疾患治療薬市場2029：新たな機会を提供する国
• 貧血およびその他の血液疾患治療薬市場2029：新たな機会を提供するセグメント
• 貧血およびその他の血液疾患治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anemia and Other Blood Disorder Drugs encompass pharmaceuticals used for the treatment of anemia and related blood disorders. These conditions typically arise when medications trigger the body's immune system to erroneously attack its own red blood cells, leading to hemolysis, a process in which red blood cells prematurely break down.

The primary categories of drugs for anemia and other blood disorders include those for iron deficiency anemia, chronic kidney disease-related anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia, a prevalent form of anemia, occurs when the blood lacks a sufficient number of healthy red blood cells responsible for transporting oxygen to the body's cells. Anemia can be further classified into microcytic (low MCV), normocytic (normal MCV), and macrocytic (high MCV) types. These drugs are administered through various methods, including oral and injectable, and are distributed through channels such as hospital pharmacies, online pharmacies, and traditional retail pharmacies.

The anemia and other blood disorder drugs market research report are one of a series of new reports from The Business Research Company that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anemia and other blood disorder drugs market size has grown strongly in recent years. It will grow from $11.61 billion in 2024 to $12.38 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, aging population, pharmaceutical innovation, patient awareness.

The anemia and other blood disorder drugs market size is expected to see strong growth in the next few years. It will grow to $16.09 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to emerging markets, global demographics, economic factors. Major trends in the forecast period include research and development, technological advances, biologics and targeted therapies, gene therapies, telemedicine and remote monitoring, orphan drug designations, mergers and acquisitions.

The rising prevalence of anemia worldwide is a significant driver for the market. Unhealthy lifestyles, shifting dietary patterns, and heightened stress levels have led to an increase in anemia cases across the globe. As an example, anemia has become a common health issue in the elderly population, with a prevalence rate of approximately 17% among those aged over 65. The World Bank has reported that anemia ranks as the 8th most prevalent disease among women and young individuals. This increase in anemia prevalence contributes to the growth of the market for anemia and other blood disorder drugs.

The increasing demand for personalized medicine is expected to drive the growth of the anemia and other blood disorder drugs market. Personalized medicine involves using an individual's genetic profile to make decisions regarding disease prevention, diagnosis, and treatment. This approach offers more effective and precisely targeted therapies for anemia and other blood disorders, leading to better and longer-lasting patient health outcomes, making medical treatment more efficient and effective. For example, in March 2023, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022, and around 12 of these therapeutic NMEs are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the increasing demand for personalized medicine is fueling the growth of the anemia and other blood disorder drugs market.

The growing utilization of biologics for the treatment of anemia and other blood disorders has become a prominent trend. Biologics are substances made from proteins, sugars, nucleic acids, or a combination of these components, often derived from living organisms like humans, animals, or microorganisms, and may contain living organism components. This increasing preference for biologics over traditional drugs has led to a reduced number of drugs used in treating anemia and other blood disorders, impacting the market. For instance, Hospira, a medical device and pharmaceutical company, submitted its initial biologics license application to the FDA for a drug designed to treat anemia. Furthermore, the FDA approved the first Epoetin Alfa biosimilar for anemia treatment associated with chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The growing adoption of biologics is expected to hinder the growth of the anemia and other blood disorder drugs market.

Companies operating in the anemia and other blood disorder drugs market are increasingly engaging in collaborative efforts with government agencies to jointly develop and commercialize specific drugs. These collaborations involve the sharing of knowledge, technology, and costs, providing a platform for addressing challenges such as expiring licenses and navigating a stringent regulatory environment. For instance, in March 2023, Disc Medicine initiated a collaboration with the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) for Phase 1/2 and Phase 2 clinical trials of biopterin in adult patients with Diamond-Blackfan Anemia (DBA) and iron deficiency anemia. These studies will be conducted and funded by the NIH through a cooperative research and development agreement (CRADA).

Leading companies in the anemia and other blood disorder drugs market are intensifying their efforts to introduce innovative medications, gaining a competitive advantage in the industry. These novel medications represent significant advancements or new approaches to treating medical conditions and diseases. For example, in August 2023, Bristol-Myers Squibb Company, a prominent US-based pharmaceutical firm, secured approval from the United States Food and Drug Administration (FDA) for Reblozyl as the first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes. Reblozyl stands out as the first therapy to demonstrate its superiority compared to erythropoiesis-stimulating agents (ESAs) in treating MDS-related anemia, as evidenced by interim results from the pivotal Phase 3 COMMANDS study. The approval was based on data from the COMMANDS study, a global Phase 3 trial showing that nearly twice as many Reblozyl-treated patients achieved transfusion independence of at least 12 weeks, along with a concurrent hemoglobin increase when compared to Epoetin alfa.

In October 2022, Pfizer, a renowned pharmaceutical company based in the United States, acquired Global Blood Therapeutics Inc. for an undisclosed sum. This strategic acquisition enabled Pfizer to enhance its drug development portfolio and offer several promising best-in-class treatments to individuals suffering from sickle cell disease. Global Blood Therapeutics Inc. is a US-based biotechnology company specializing in the field of anemia and other blood disorder drugs.

Major companies operating in the anemia and other blood disorder drugs market include Amgen Inc., GlaxoSmithKline PLC, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc

North America was the largest region in the anemia and other blood disorder drugs market in 2024. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anemia And Other Blood Disorder Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anemia and other blood disorder drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anemia and other blood disorder drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anemia and other blood disorder drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Iron Deficiency Anemia; Chronic Kidney Disease Anemia; Sickle Cell Anemia; Aplastic Anemia
• 2) By Route of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospitals Pharmacy; Online Pharmacy; Pharmacy
• Subsegments:
• 1) By Iron Deficiency Anemia: Oral Iron Supplements; Injectable Iron Supplements; Iron Fortified Foods
• 2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs); Iron Supplements; Blood Transfusion
• 3) By Sickle Cell Anemia: Hydroxyurea; Blood Transfusions; Gene Therapy; Pain Management Drugs
• 4) By Aplastic Anemia: Immunosuppressive Therapy; Stem Cell Transplantation; Erythropoiesis-Stimulating Agents (ESAs)
• Companies Mentioned: Amgen Inc; GlaxoSmithKline plc; Akebia Therapeutics Inc.; Bayer AG; Pfizer Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anemia And Other Blood Disorder Drugs Market Characteristics

3. Anemia And Other Blood Disorder Drugs Market Trends And Strategies

4. Anemia And Other Blood Disorder Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anemia And Other Blood Disorder Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anemia And Other Blood Disorder Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anemia And Other Blood Disorder Drugs Market Growth Rate Analysis
• 5.4. Global Anemia And Other Blood Disorder Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anemia And Other Blood Disorder Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anemia And Other Blood Disorder Drugs Total Addressable Market (TAM)

6. Anemia And Other Blood Disorder Drugs Market Segmentation

• 6.1. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Iron Deficiency Anemia
• Chronic Kidney Disease Anemia
• Sickle Cell Anemia
• Aplastic Anemia
• 6.2. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacy
• Online Pharmacy
• Pharmacy
• 6.4. Global Anemia And Other Blood Disorder Drugs Market, Sub-Segmentation Of Iron Deficiency Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Iron Supplements
• Injectable Iron Supplements
• Iron Fortified Foods
• 6.5. Global Anemia And Other Blood Disorder Drugs Market, Sub-Segmentation Of Chronic Kidney Disease Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erythropoiesis-Stimulating Agents (ESAs)
• Iron Supplements
• Blood Transfusion
• 6.6. Global Anemia And Other Blood Disorder Drugs Market, Sub-Segmentation Of Sickle Cell Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydroxyurea
• Blood Transfusions
• Gene Therapy
• Pain Management Drugs
• 6.7. Global Anemia And Other Blood Disorder Drugs Market, Sub-Segmentation Of Aplastic Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressive Therapy
• Stem Cell Transplantation
• Erythropoiesis-Stimulating Agents (ESAs)

7. Anemia And Other Blood Disorder Drugs Market Regional And Country Analysis

• 7.1. Global Anemia And Other Blood Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anemia And Other Blood Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anemia And Other Blood Disorder Drugs Market

• 8.1. Asia-Pacific Anemia And Other Blood Disorder Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anemia And Other Blood Disorder Drugs Market

• 9.1. China Anemia And Other Blood Disorder Drugs Market Overview
• 9.2. China Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anemia And Other Blood Disorder Drugs Market

• 10.1. India Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anemia And Other Blood Disorder Drugs Market

• 11.1. Japan Anemia And Other Blood Disorder Drugs Market Overview
• 11.2. Japan Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anemia And Other Blood Disorder Drugs Market

• 12.1. Australia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anemia And Other Blood Disorder Drugs Market

• 13.1. Indonesia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anemia And Other Blood Disorder Drugs Market

• 14.1. South Korea Anemia And Other Blood Disorder Drugs Market Overview
• 14.2. South Korea Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anemia And Other Blood Disorder Drugs Market

• 15.1. Western Europe Anemia And Other Blood Disorder Drugs Market Overview
• 15.2. Western Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anemia And Other Blood Disorder Drugs Market

• 16.1. UK Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anemia And Other Blood Disorder Drugs Market

• 17.1. Germany Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anemia And Other Blood Disorder Drugs Market

• 18.1. France Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anemia And Other Blood Disorder Drugs Market

• 19.1. Italy Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anemia And Other Blood Disorder Drugs Market

• 20.1. Spain Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anemia And Other Blood Disorder Drugs Market

• 21.1. Eastern Europe Anemia And Other Blood Disorder Drugs Market Overview
• 21.2. Eastern Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anemia And Other Blood Disorder Drugs Market

• 22.1. Russia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anemia And Other Blood Disorder Drugs Market

• 23.1. North America Anemia And Other Blood Disorder Drugs Market Overview
• 23.2. North America Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anemia And Other Blood Disorder Drugs Market

• 24.1. USA Anemia And Other Blood Disorder Drugs Market Overview
• 24.2. USA Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anemia And Other Blood Disorder Drugs Market

• 25.1. Canada Anemia And Other Blood Disorder Drugs Market Overview
• 25.2. Canada Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anemia And Other Blood Disorder Drugs Market

• 26.1. South America Anemia And Other Blood Disorder Drugs Market Overview
• 26.2. South America Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anemia And Other Blood Disorder Drugs Market

• 27.1. Brazil Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anemia And Other Blood Disorder Drugs Market

• 28.1. Middle East Anemia And Other Blood Disorder Drugs Market Overview
• 28.2. Middle East Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anemia And Other Blood Disorder Drugs Market

• 29.1. Africa Anemia And Other Blood Disorder Drugs Market Overview
• 29.2. Africa Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anemia And Other Blood Disorder Drugs Market Competitive Landscape And Company Profiles

• 30.1. Anemia And Other Blood Disorder Drugs Market Competitive Landscape
• 30.2. Anemia And Other Blood Disorder Drugs Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Akebia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Anemia And Other Blood Disorder Drugs Market Other Major And Innovative Companies

• 31.1. F. Hoffmann-La Roche Ltd.
• 31.2. Merck Sharp & Dohme Corp.
• 31.3. Novartis AG
• 31.4. Global Blood Therapeutics Inc.
• 31.5. GlycoMimetics Inc.
• 31.6. Eli Lilly and Company
• 31.7. FibroGen Inc.
• 31.8. bluebird bio Inc.
• 31.9. Acceleron Pharma Inc.
• 31.10. AMAG Pharmaceuticals Inc.
• 31.11. Pieris Pharmaceuticals Inc.
• 31.12. Vifor Pharma Management Ltd.
• 31.13. Sanofi S.A.
• 31.14. Allergan U.S. Inc.
• 31.15. Meda Consumer Healthcare Inc.

32. Global Anemia And Other Blood Disorder Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anemia And Other Blood Disorder Drugs Market

34. Recent Developments In The Anemia And Other Blood Disorder Drugs Market

35. Anemia And Other Blood Disorder Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Anemia And Other Blood Disorder Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anemia And Other Blood Disorder Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anemia And Other Blood Disorder Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer